Abstract: A simple, accurate, rapid and precise reverse phase high performance liquid chromatographic method was developed for simultaneous estimation of Irbesartan and Atorvastatinin synthetic mixture. Inertsil C 18 , 150 mm x 4.6 mm, 5 μm particle size in gradient mode with mobile phase Acetonitrile: 0.1% Formic acid (40: 60 v/v) and pH adjusted to 3.5 ± 0.1 with orthophosphoric acid was used. The flow rate was 1.0 ml/min and absorbance of individual component was measured at 262 nm. The retention times of Irbesartan and Atorvastatin were found to be 3.993 and 7.733 min, respectively. Linearity for Irbesartan and Atorvastatin was in the range of 400 -800 and 50-100μg/ml with correlation coefficient values 0.9995and 0.9994, the percentage recovery obtained was 99.88and 99.70 %, respectively.
Introduction:
The present study was aimed to develop simple, rapid and precise analytical method for simultaneous estimation of Irbesartan (IRB) and Atorvastatin (ATR).
Irbesartan, an angiotensin II receptor antagonist (1) . is used mainly for the treatment of hypertension. It is an orally active nonpeptidetetrazole derivative and selectively inhibits angiotensin II receptor type 2. Angiotensin II receptor type1 antagonists have been widely used in treatment of diseases like hypertension, heart failure, myocardial infarction and diabetic nephropathy. IUPAN name of Irbesartan is 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro [4.4] non-1-en-4-one. Irbesartan is white or almost white, crystalline powder. Solubility is given in practically insoluble in water, sparingly soluble in methanol, slightly soluble in methylene chloride.
Atorvastatin is used as lipid-lowering agents used in hyperlipidaemia condition. Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase.
(4)
As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, these results in a subsequent decrease in hepatic cholesterol levels and decreases blood cholesterol level. Atorvastatin is white oral most white, crystalline powder. Solubility is given in practically insoluble in water, soluble in methanol, slightly soluble in methylene chloride.
Hypertension frequently coexists with hyperlipidaemia and both are considered to be major risk factors for developing cardiac disease ultimately resulting in adverse cardiac events. This clustering of risk factors is potentially due to a common mechanism. Further, patient compliance with the management of hypertension is generally better than patient compliance with hyperlipidaemia. It would therefore be advantageous for patients to have a single therapy which treats both of these conditions with help of fixed dose combination of Irbesartan and atorvastatin. The review of literature regarding quantitative analysis of Irbesartan and atorvastatin revealed that no attempt was made to develop analytical methods for Irbesartan and atorvastatin. Some spectrometric methods and chromatographic methods have been reported for the estimation of the individual drugs.The focus of the present study was to develop and validate a rapid, stable, specific, and economic high performance liquid chromatographic method for the estimation of Irbesartan and atorvastatin in Synthetic mixture. 
Materials and Methods

Chemicals and Reagents
Irbesartanraw material was received as gift sample from CTX Life science, Surat. Atorvastatinraw material was received as gift sample from J.B. Chemicals, Ankleshwar. Methanol HPLC Grade (Finar),HPLC Grade Water, Acetonitrile HPLC Grade (Finar), Potassium dihydrogen Phosphate (Merck),Ortho Phosphoric Acid AR Grade (Merck) was used for development purpose.
Instruments and Chromatographic conditions
Chromatographic analysis was carried out on a prominence liquid chromatograph (UFLC Shimadzu Corporation, Tokyo, Japan) with LC-2010AHT series binary pump systems, Auto injection system, temperature controller (system controller and a UV detector (LC-2010). CLASS-VP (version 2.31) software was used to acquire and process the data.Semi micro analytical balance (Sartorius CD2250, Germany) was used for weighing purpose. Unisphere C 18 column (Agela Tech.) (5 µm, 250mm × 4.6 mm i.d) was used for method development purpose.HPLC water was obtained using arium ® 611VF (Sartorius).Magnetic stirrer (Remi) was used for mixing purpose.PH tutor (313927, Eutech Instruments) was used for pH measurement. Sonication of solutions was done using Ultrasonic cleaner (D 120/1H, Trans-O-Sonic).Nylon membrane filters (0.22 µm, 47 mm D) were used for filtration purpose.
All volumetric glassware used was calibrated.
Preparation of Reagents and Standards
Mobile phase
The mobile phase consisted of mixture of Acetonitrile: 0.1% formic acidin ratio of (40: 60, v/v) and adjust pH 3.5 with Ortho phosphoric acid. The mode for was Gradient. The mobile phase was filtered through a 0.22 µm nylon membrane filter and degassed prior to use.
Preparation of Standard Stock Solutions Preparation Standard solution of Irbesartan
A standard stock solution of IRB (1000 µg/ml) was prepared separately by dissolving 10mg of drug in 10ml mobile phase -Acetonitrile: 0.1% Formic acid (40:60, v/v).
Preparation working standard solution of Irbesartan
400µg/ml of IRB stock solution was prepared by diluting 4 ml stock solution to 10 ml with mobile phaseAcetonitrile: 0.1% Formic acid (40:60, v/v)
Preparation Standard solution of Atorvastatin
A standard stock solution of ATR (1000µg/ml) was prepared separately by dissolving 10mg of drug in 10ml mobile phase -Acetonitrile: 0.1% Formic acid (40:60, v/v).1 ml of stock solution diluted up to 10 ml of mobile phase give 1000µg/ml solution of Atorvastatin as a stock solution.
Preparation Standard solution of Irbesartan and Atorvastatin in combination
4 ml from working standard stock solutions of IRB (1000µg/ml) and 0.5 ml from working standard stock solutions of ATR (100µg/ml) were taken in a common volumetric flask diluted up to 10ml with mobile phase -Acetonitrile: 0.1% Formic acid (40:60, v/v) to make final concentration IRB (400µg/ml) and ATR (50µg/ml). Finally the solution had concentration 16000μg/ml for IRB and 2000μg/ml for ATR. from that pipette out 1ml in 10 ml volumetric flask and volume was made up to mark with mobile phase -Acetonitrile: 0.1% Formic acid (40:60, v/v) to make final concentration IRB (10µg/ml) and ATR (250µg/ml).
Preparation of Test (formulation) Solution
Chromatogram of the Test solution containing 560µg/ml of IRB and 70µg/ml of ATR was recorded and peak areas were noted for estimation of IRB and ATR.
Validation of the Developed Method (10)
The developed method of analysis was validated as per the ICH guidelines for the parameters like system suitability, specificity, linearity, precision, accuracy and system suitability, limit of detection (LOD) and limit of quantitation (LOQ).
Selection Of Wavelength
Selection of wavelength was carried out using UV spectrophotometer. Both the drugs were detected at 262nm. (Figure 3 
Mobile Phase Selection
Various mobile phases with different ratio of different solvents and pH were used are shown in Table 1 . The mixture of acetonitrile and 0.1% formic acid in ratio of (40: 60, v/v) provided optimum polarity for proper migration, separation and resolution of Irbesartan and Atorvastatin peaks. Under these conditions, the eluted peaks were well defined, resolved and free from tailing.
Due to the non-polar nature of the stationary phase more polar component Atorvastatin will be eluted first because of its more affinity towards the polar mobile phase and less polar component Irbesartan will be eluted later due to its more affinity towards non-polar stationary phase. 
I. Intraday precision
The data for intraday precision for combined standard solution of IRB and ATR is presented in Table3.
The% R.S.D was found to be0.010-0.017 % for IRB and 0.020-0.058 % for ATR.
These % RSD value was found to be less than±1.0 indicated that the method is precise. 
II. Interday precision
The data for inter day precision for combined standard solution of IRB and ATR is presented in Table 4 .
The % R.S.D was found to be0.010-0.021 % for IRB and 0.023-0.054 % for ATR.
Accuracy
Accuracy of the method was determined by recovery study from synthetic mixture at three levels (80%, 100%, and 120%) of standard addition.
The% recovery values are tabulated in Table 5 and 6.
Percentage recovery for IRB and ATR by this method was found in the range of99.98 to 100.26% and99.81 to 100.04%, respectively.
The value of % RSD within the limit indicated that the method is accurate and percentage recovery shows that there is no interference from the excipients. 
Limit of detection and quantitation
The LOD for IRB and ATR was conformed to be 0.033µg/mland 0.101µg/ml, respectively.
The LOQ for IRB and ATR was conformed to be 0.028 µg/ml and 0.086µg/ml, respectively. The obtained LOD
and LOQ results are presented in Table 7 . 
Robustness
The obtained Ruggedness and Robustness results are presented in table8
The% R.S.D was found to be 0.0072-0.021 for IRB and0.011-0.041% for ATR.
These % RSD value was found to be less than±1.0 indicated that the method is precise. No significant changes in the Peak area were observed, proving that the developed method is rugged and robust. 
Application of the Proposed Method for Analysis of IRB and ATRIN Synthetic Mixture
Chromatogram of the Test solution containing 560µg/ml of IRB and 70µg/ml of ATR was recorded and peak areas were noted for estimation of IRB and ATR, respectively.
The concentration of IRB and ATR in synthetic mixture was determined against the standard IRB and ATR.
The results from the analysis of synthetic mixture containing Irbesartan (560µg/ml)and Atorvastatin (70µg/ml) in combination are presented in table in 9.
The percent assay shows that there is no interference from excipients and the proposed method can successfully applied to analysis of commercial formulation containing IRB and ATR. The %assay values are tabulated in Table 9 . 
